0000950170-24-080012.txt : 20240702 0000950170-24-080012.hdr.sgml : 20240702 20240702073003 ACCESSION NUMBER: 0000950170-24-080012 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240628 FILED AS OF DATE: 20240702 DATE AS OF CHANGE: 20240702 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kathiresan Sekar CENTRAL INDEX KEY: 0001864112 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40489 FILM NUMBER: 241092908 MAIL ADDRESS: STREET 1: 500 TECHNOLOGY SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Verve Therapeutics, Inc. CENTRAL INDEX KEY: 0001840574 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 824800132 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 201 BROOKLINE AVENUE STREET 2: SUITE 601 CITY: BOSTON STATE: MA ZIP: 02215 BUSINESS PHONE: (978) 501-3026 MAIL ADDRESS: STREET 1: 201 BROOKLINE AVENUE STREET 2: SUITE 601 CITY: BOSTON STATE: MA ZIP: 02215 4 1 ownership.xml 4 X0508 4 2024-06-28 0001840574 Verve Therapeutics, Inc. VERV 0001864112 Kathiresan Sekar C/O VERVE THERAPEUTICS, INC. 201 BROOKLINE AVENUE, SUITE 601 BOSTON MA 02215 true true false false Chief Executive Officer false Common Stock 2024-06-28 4 M false 30000 2.87 A 351128 D Common Stock 240997 I Kathiresan Family 2021 Irrevocable Trust Common Stock 80997 I Sekar Kathiresan 2021 Irrevocable Trust Stock Option (right to buy) 2.87 2024-06-28 4 M false 30000 0 D 2030-09-15 Common Stock 30000 215308 D Stock Option (right to buy) 2.87 2030-09-15 Common Stock 160000 160000 I Sekar Kathiresan 2022 Annuity Trust Stock Option (right to buy) 2.87 2030-09-15 Common Stock 200000 200000 I Sekar Kathiresan 2023 Annuity Trust Includes 4,918 shares of the Company's common stock acquired under the Verve Therapeutics, Inc. Amended and Restated 2021 Employee Stock Purchase Plan. The remaining shares underlying this option, which was granted on September 16, 2020, vest in equal monthly installments until September 16, 2024. The shares underlying the option were fully vested when transferred. /s/ Andrew Ashe, as Attorney-in-Fact for Sekar Kathiresan 2024-07-02